Browsing by Author "Chuaqui, RF"

Now showing 1 - 2 of 2
  • Thumbnail Image
    Item
    Molecular alterations in primary prostate cancer after androgen ablation therapy
    (AMER ASSOC CANCER RESEARCH, 2005) Best, CJM; Gillespie, JW; Yi, YJ; Chandramouli, GVR; Perlmutter, MA; Gathright, Y; Erickson, HS; Georgevich, L; Tangrea, MA; Duray, PH; Gonzalez, S; Velasco, A; Linehan, WM; Matusik, RJ; Price, DK; Figg, WD; Emmert Buck, MR; Chuaqui, RF
    Purpose: After an initial response to androgen ablation, most prostate tumors recur, ultimately progressing to highly aggressive androgen-independent cancer. The molecular mechanisms underlying progression are not well known in part due to the rarity of androgen-independent Samples from primary and-metastatic sites.
  • Thumbnail Image
    Item
    Molecular differentiation of high- and moderate-grade human prostate cancer by cDNA microarray analysis
    (LIPPINCOTT WILLIAMS & WILKINS, 2003) Best, CJM; Leiva, IM; Chuaqui, RF; Gillespie, JW; Duray, PH; Murgai, M; Zhao, YD; Simon, R; Kang, JJ; Green, JE; Bostwick, DG; Linehan, WM; Emmert Buck, MR
    The prognosis of men with moderate-grade prostate cancer is uncertain. At present, there are few if any reliable molecular markers that can distinguish moderate-grade tumors from those that behave more aggressively. To better understand the molecular basis of human prostate cancer and potentially provide information toward more accurate prognosis, we measured and analyzed gene expression profiles of 13 high- and moderate-grade human prostate tumors using cDNA microarrays. The expression of 136 genes was observed to differ significantly (P < 0.001) between normal prostate and tumors using one-sample t testing and Wilcoxon ranking. Hierarchical clustering of genes demonstrated a relatively similar pattern of differential expression across the tumors. However, importantly, permutation t tests (two-tailed P < 0.001) revealed 21 genes whose expression profiles segregated moderate- and high-grade tumors from each other, which was significantly (P < 0.03) Greater than what was expected by chance. These results were compared in silico with prostate cancer profiling efforts performed by other groups, including a meta-analysis of four data sets. which validated many of the dysregulated genes. We suggest that these data provide insight into the molecular nature of clinically aggressive prostate cancer.